Scleradec I showed a 69% improvement in Raynaud's Condition Score at 6 months (P<.001). At 36 months the improvement was 90% from original baseline (P<.0001)
The TAM (total available market) for Raynaud's is 20x larger than Scleroderma according to Hedrick's data source. What I found interesting in this link was the comment that Raynaud's phenomenon is a precursor to Scleroderma. As with all of these autoimmune diseases, the sooner the condition is diagnosed and treated the better.
The National Institute of Arthritis and Musculoskeletal and Skin Diseases estimates that the number of people in the United States with systemic sclerosis ranges from 40,000 to 165,000. A survey that included all scleroderma-related disorders, including Raynaud's phenomenon, suggested a number between 250,000 and 992,500.
This numbers show also the much more bigger market for Raynaud's phenomenon
In addition to its substantial contribution to the disease burden of scleroderma, RP is a source of significant morbidity in several more common autoimmune and inflammatory conditions including rheumatoid arthritis, systemic lupus erythematosus (lupus), and Sjogren’s syndrome. The worldwide prevalence of moderate-to-severe RP in these three diseases alone exceeds one million patients, providing an estimated peak annual revenue potential of $1.6 billion.